ALZN Key Statistics, Chart & Performance
The current stock price of ALZN is 2.15 USD. In the past month the price decreased by -11.89%. In the past year, price decreased by -78.48%.
ALZN Latest News, Press Relases and Analysis
ALZN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.44B | ||
| AMGN | AMGEN INC | 14.91 | 175.55B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.89 | 114.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.66 | 78.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 768.82 | 51.80B | ||
| INSM | INSMED INC | N/A | 42.33B | ||
| NTRA | NATERA INC | N/A | 31.12B | ||
| BIIB | BIOGEN INC | 10.28 | 25.25B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.36 | 22.00B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.28B | ||
| INCY | INCYTE CORP | 15.21 | 19.17B |
Related stock screener links
About ALZN
Company Profile
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company is headquartered in Atlanta, Georgia and currently employs 4 full-time employees. The company went IPO on 2021-06-15. The firm is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The firm's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
Company Info
ALZAMEND NEURO INC
480 Peachtree Road Ne, Second Floor, Suite 103
Atlanta GEORGIA US
CEO: Stephan Jackman
Employees: 4
Phone: 18447226333
ALZAMEND NEURO INC / ALZN FAQ
What does ALZAMEND NEURO INC do?
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company is headquartered in Atlanta, Georgia and currently employs 4 full-time employees. The company went IPO on 2021-06-15. The firm is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The firm's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
What is the stock price of ALZAMEND NEURO INC today?
The current stock price of ALZN is 2.15 USD. The price decreased by -0.46% in the last trading session.
What is the dividend status of ALZAMEND NEURO INC?
ALZN does not pay a dividend.
How is the ChartMill rating for ALZAMEND NEURO INC?
ALZN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of ALZAMEND NEURO INC (ALZN) based on its PE ratio?
ALZAMEND NEURO INC (ALZN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-247.95).
Can you provide the ownership details for ALZN stock?
You can find the ownership structure of ALZAMEND NEURO INC (ALZN) on the Ownership tab.
ALZN Technical Analysis
ALZN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALZN. ALZN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ALZN Financial Highlights
Over the last trailing twelve months ALZN reported a non-GAAP Earnings per Share(EPS) of -247.95. The EPS decreased by -22.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -108.85% | ||
| ROE | -128.89% | ||
| Debt/Equity | 0 |
ALZN Forecast & Estimates
8 analysts have analysed ALZN and the average price target is 42.84 USD. This implies a price increase of 1892.56% is expected in the next year compared to the current price of 2.15.